Preparation, Properties, Reactions, and Adenosine Receptor Affinities of Sulfophenylxanthine Nitrophenyl Esters: Toward the Development of Sulfonic Acid Prodrugs with Peroral Bioavailability

Journal of Medicinal Chemistry

Volumn 47, Issue 4, 2004, Pages 1031-1043

  Yan, Luo ^a   Müller, Christa E ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Pharmazeutisches Institut   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 PROPYL 8 (4 SULFOPHENYLXANTHINE); 1 PROPYL 8 [4 [(4 NITROPHENOXY)SULFONYL]PHENYL]XANTHINE; 4 (NITROPHENOXYSULFONYL)BENZOIC ACID; 5,6 DIAMINOURACIL; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; BENZENESULFONIC ACID DERIVATIVE; BENZOIC ACID DERIVATIVE; CYANAMIDE; ESTER DERIVATIVE; PRODRUG; PSB 1115; PURINE P2 RECEPTOR; SULFONIC ACID DERIVATIVE; SULFOPHENYLXANTHINE NITROPHENYL DERIVATIVE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; XANTHINE 3 NITROPHENYLSULFONATE;

ACIDITY; ANIMAL TISSUE; ARTICLE; CAPILLARY ELECTROPHORESIS; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME STABILITY; HUMAN; HYDROLYSIS; ISOMER; LIPOPHILICITY; LIVER HOMOGENATE; NONHUMAN; PH; POLYMERIZATION; RAT; RING CLOSING METATHESIS; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CATTLE; CELL LINE; CRICETINAE; DRUG STABILITY; ESTERS; HUMANS; HYDROLYSIS; LIVER; NITROBENZENES; PRODRUGS; RADIOLIGAND ASSAY; RATS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONIC ACIDS; XANTHINES;

EID: 0842282741     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0310030     Document Type: Article

References (49)

1. Burnstock, G. A basis for distinguishing two types of purinergic receptor. In Cell Membrane Receptors for Drugs and Hormones; Bolis, L., Straub, R. W., Eds.; Raven Press: New York, 1978; pp 107-118.
2. Hess, S. Recent advances in adenosine receptor antagonist research. Exp. Opin. Ther. Pat. 2001, 11, 1533-1561.
3. (b) Müller, C. E.; Stein, B. Adenosine receptor antagonists: Structures and potential therapeutic applications. Curr. Pharm. Des. 1996, 2, 501-530.
4. (c) Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552.
5. Guile, S. D.; Ince, F.; Ingall, A. H.; Kindon, N. D.; Meghani, P.; Mortimore, M. P. The medicinal chemistry of the P2 receptor family. Prog. Med. Chem. 2001, 38, 115-187.
6. (b) Müller, C. E. P2-Pyrimidinergic receptors and their ligands. Curr. Pharm. Des. 2002, 26, 2353-2369.
7. (c) Fischer, B. Therapeutic application of ATP (P2)-receptors agonists and antagonists. Exp. Opin. Ther. Pat. 1996, 9, 385-399.
8. (d) Ogilvie, A.; Blasius, R.; Schulze-Lohoff, E.; Sterzel, R. B. Adenine dinucleotides: a novel class of signaling molecules. J. Auton. Pharmacol. 1996, 16, 325-328.
9. (e) Benoit, P.; Dogne, J. M. Platelet ADP receptors and their antagonists. Mini Rev. Med. Chem. 2003, 3, 145-148.
10. (f) Jacobson, K. A.; Jarvis, M. F.; Williams, M. Purine and pyrimidine (P2) receptors as drug targets. J. Med. Chem. 2002, 45, 4057-4093.
11. (g) Shaver, S. R. P2Y receptors: biological advances and therapeutic opportunities. Curr. Opin. Drug Discovery Dev. 2001, 4, 665-670.
12. Lambrecht. G.; Braun, K.; Damer, S.; Ganso, M.; Hildebrandt, C.; Ullmann, H.; Kassack, M. U.; Nickel, P. Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr. Pharm. Des. 2002, 26, 2371-2399.
13. 2-adenosine receptors. J. Med. Chem. 1985, 28, 487-492.
14. Hamilton, H. W.; Ortwine, D. F.; Worth, D. F.; Badger, E. W.; Bristol, J. A.; Bruns, R. F.; Haleen, S. J.; Steffen, R. P. Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application. J. Med. Chem. 1985, 28, 1071-1079.
15. 2B-selective adenosine receptor antagonists. J. Med. Chem. 2002, 45, 1500-1510.
16. 13C NMR. Tetrahedron Lett. 1975, 42, 3639-3642.
17. Baumgold, J.; Nikodijevic, O.; Jacobson, K. A. Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding. Biochem. Pharmacol. 1992, 43, 889-894.
18. Finlayson, K.; Butcher, S. P.; Sharkey, J.; Olverman, H. J. Detection of adenosine receptor antagonists in rat brain using a modified radioreceptor assay. J. Neurosci. Methods 1997, 77, 135-142.
19. Evoniuk, G.; Von Borstel, R. W.; Wurtman, R. J. Antagonism of the cardiovascular effects of adenosine by caffeine or 8-(p-sulfophenyl)theophylline. J. Pharmacol. Exp. Ther. 1987, 240, 428-432.
20. Volonte, C.; Ciotti, M. T.; D'Ambrosi, N.; Lockhart, B.; Spedding, M. Neuroprotective effects of modulators of P2 receptors in primary culture of CNS neurones. Neuropharmacology 1999, 38, 1335-1342.
21. Roche, E. B., Ed. Bioreversible carriers in drug design: Theory and application; Pergamon Press: Oxford, 1987.
22. Testa, B.; Mayer, J. M. Hydrolysis in drug and prodrug metabolism. Chemistry, biochemistry, and enzymology; Verlag Helvetica Chimica Acta: Zürich, 2003.
23. Roth, H. J.; Fenner, H. Arzneistoffe: Struktur, Bioreaktivität, Wirkungsbezogene Eigenschaften; Deutscher Apotheker Verlag: Stuttgart, 2000; p 168.
24. 7 Receptor. J. Med. Chem. 2003, 46, 1318-1329.
25. Kochi, J. K.; Hammond, G. S. Benzyl tosylates. II. The application of the Hammett Equation to the rates of their solvolysis. J. Am. Chem. Soc. 1953, 3445-3550.
26. Davy, M. B.; Douglas, K. T.; Loran, J. S.; Steltner, A.; Williams, A. Elimination-addition mechanisms of acyl group transfer: Hydrolysis and aminolysis of aryl phenylmethanesulfonates. J. Am. Chem. Soc. 1977, 99, 1196-1206.
27. Suttle, N. A.; Williams, A. Ammonolysis of aryl toluenesulphonate esters: Evidence for the concerted displacement of the aryl oxide group. J. Chem. Soc., Perkin Trans. 2 1983, 1563-1567.
28. Stang, P. J. Alkynyl carboxylate, phosphate, and sulfonate esters. Acc. Chem. Res. 1991, 24, 304-310.
29. Allen, A. D.; Kitamura, T.; Roberts, K. A.; Stang, P. J.; Tidwell, T. T. Hydrolysis mechanisms of alkynyl benzoates, tosylates and phosphates. J. Am. Chem. Soc. 1988, 110, 622-624.
30. Pregel, M. J.; Buncel, E. Nucleophilic displacement reactions at carbon, phosphorus and sulfphur centres: Reaction of aryl methanesulphonates with ethoxide, change in mechanism with change in leaving group. J. Chem. Soc., Perkin Trans. 2 1991, 307-311.
31. Kochi, J. K.; Hammond, G. S. Benzyl tosylate. I. Preparation and properties. J. Am. Chem. Soc. 1953, 3443-3444.
32. Shamim, M. T.; Ukena, D.; Padgett, W. L.; Daly, J. W. Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. J. Med. Chem. 1989, 32, 1231-1237.
33. Müller, C. E.; Shi, D.; Manning, M.; Daly, J. W. Synthesis of paraxanthine analogues (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. J. Med. Chem. 1993, 36, 3341-3349.
34. Everard, B. A.; Mills, J. A. Methods of resolution. Part II. N-(-)-methyl-p-sulphamyl benzoic acid. J. Chem. Soc. 1950, 3386-3388.
35. Datta, S. K.; Grundmann, C.; Bhattacharyya, N. K. An abnormal Schmidt Reaction: 4,5-Dihydro-1H-1-benzazepin-2(3H)-one from γ-phenylbutyric acid. J. Chem. Soc., Chem. Commun. 1970, 2058-2060.
36. Traxler, P. M.; Wacker, O.; Bach, H. L.; Geissler, J. F.; Kump, W.; Meyer, T.; Regenass, U.; Roesel, J. L.; Lydon, N. Sulfonyl-benzoyl-nitrostyrenes: Potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase. J. Med. Chem. 1991, 34, 2328-2337.
37. Müller, C. E. Formation of oxazolo [3,2-α]purinones from propynyluracils. J. Org. Chem. 1994, 59, 1928-1929.
38. 2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. 2004, 308, 1-9.
39. Wätzig, H.; Dette, C. Capillary electrophoresis (CE) - a review. Strategies for method development and application related to pharmaceutical and biological sciences. Pharmazie 1994, 49, 83-96.
40. Daly, J. W. In Role of adenosine and adenine nucleotides in the biological system; Imai, S., Nakazawa, M., Eds.; Elsevier Science Publishers: New York, 1991; p 119.
41. 2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positoins. J. Med. Chem. 2002, 45, 2131-2138.
42. 3 adenosine receptor with widespread tissue distribution. Mol. Pharmacol. 1993, 44, 524-532.
43. 2 receptor subtypes. Mol. Pharmacol. 1993, 43, 909-914.
44. Blicke, F. F.; Godt, H. C. Reactions of 1,3-dimethyl-5,6-diaminouracil. J. Am. Chem. Soc. 1954, 76, 2798-2800.
45. Papesch, V.; Schroeder, E. Synthesis of 1-mono-and 1,3-disubstituted 6-aminouracils. Diruetic activity. J. Org. Chem. 1951, 16, 1879-1890.
46. Müller, C. E. Synthesis of 3-substituted 6-aminouracils. Tetrahedron Lett. 1991, 32, 6539-6540.
47. Müller, C. E. General synthesis and properties of 1-monosubstituted xanthines. Synthesis 1993, 125-128.
48. Güven, K. C.; Özaydin, F. Stability of sodium cyclamate in simulated gastric and intestinal media. Pharmazie 1981, 36, 297.
49. Oliyai, R.; Shaw, J. P.; Sueoka-Lennen, C. M.; Cundy, K. C.; Arimilli, M. N.; Jones, R. J.; Lee, W. A. Aryl ester prodrugs of cyclic HPMPC. I: Physicochemical characterization and in vitro biological stability. Pharm. Res. 1999, 16, 1687-1693.